Cochlear Limited

CHEOY | OTC

Price Alert Chart Builder DCF Calculator

$49.30

-$0.96 (-1.91%)

Nov 2, 2026, 11:18 AM ET · Market open

Overview Rating Statistics Financials Earnings Ownership Dividends Profile

-1.91%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

-2.9 pts

Fundamentals Average

Market Sentiment Neutral

Moat Wide

Sector Rank #295/1028 (Top 29%)

Full Analysis

Key Statistics

Market Data

Market Cap $6.47B

1D Range

47.76 49.52

52W Range

31.90 97.58

Valuation (TTM)

PE 33.08

PB 5.46

EV/EBITDA 23.41

Valuation (NTM)

Forward PE 26.08

Forward PEG 6.23

Price Target $117.00

Cash Flow

FCF Yield 3.3%

SBC Adj. FCF Yield 3.3%

SBC Impact N/A

Margins

Gross Margin 70.5%

Operating Margin 12.9%

FCF Margin 13.2%

Growth (CAGR)

Revenue 3Y | 5Y 20.0% | 15.6%

Dil EPS 3Y | 5Y -26.7% | -7.5%

FCF 3Y | 5Y 1.2% | 14.4%

Returns

ROA 5.7%

ROE 8.0%

ROIC 10.2%

Financial Health

Net Cash

A$145.7M ($100.8M)

Current Ratio 2.15

Interest Coverage 22.80

Dividends

Div Yield 2.41%

Payout Ratio 54.1%

FCF Payout Ratio 91.6%

All Key Statistics

Loading financial charts...

Profile

Cochlear Limited is a global healthcare company specializing in advanced auditory solutions. It develops and manufactures surgically implanted hearing devices for individuals of all ages, from childre...

Sector Healthcare

Industry Medical - Devices

Employees 5,400

IPO Date Apr 5, 2010

Website www.cochlear.com

Fiscal Year n/a

Full Company Profile

Latest News

7 days ago · seekingalpha.com

Cochlear Limited (CHEOY) Shareholder/Analyst Call Prepared Remarks Transcript

1 month ago · businesswire.com

Cochlear Reaches More Than 1 Million Hours of Patient Experience Across Its Fully Implantable Hearing Technology Research Program

SYDNEY--(BUSINESS WIRE)--Cochlear today announced the completion of recruitment for the worldwide pivotal trial program evaluating fully implantable hearing technology. Patients across Cochlear's fully implantable hearing system research programs have experienced more than 1 million hours with their device to date. This reflects the most comprehensive research program focused on fully implantable hearing technology, underscoring Cochlear's long-term commitment to this new category. Through a ri.

3 months ago · seekingalpha.com

Cochlear Limited (CHEOY) Q4 2026 Earnings Call Transcript

4 months ago · newsfilecorp.com

Envoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implant

Mean CNC word recognition scores for Stage 1 cohort improved to 53.2% at 12 months from 15.2% pre-implantation, a 38.0 percentage point gain that continued to build on the 24.0 percentage point improvement reported at 6 months White Bear Lake, Minnesota--(Newsfile Corp. - July 14, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced positive 12-month data from the first 10 participants in Stage 1 of its pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. The Stage 1 cohort demonstrated a mean Consonant-Nucleus-Consonant ("CNC") word recognition score of 53.2% at their 12-month visits, up from a mean pre-implantation baseline of 15.2% — a 38.0 percentage point improvement.